Pharmacological prevention and treatment in clinical at-risk states for psychosis

Current Pharmaceutical Design

Volumn 18, Issue 4, 2012, Pages 550-557

  Ruhrmann, Stephan ^a   Klosterkötter, Joachim ^a   Bodatsch, Mitja ^a   Bechdolf, Andreas ^a   Schimmelmann, Benno Graf ^a   Nikolaides, Alexandra ^a   Hilboll, Desiree ^a   Schultze Lutter, Frauke ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b University Hospital of Child and Adolescent Psychiatry   (Switzerland)

Author keywords

Antidepressants; Antipsychotics; At risk; Early intervention; Omega 3 fatty acids; Prevention; Psychosis

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; GLYCINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; PLACEBO; RISPERIDONE; SERTRALINE;

AKATHISIA; ARTICLE; COGNITIVE THERAPY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE INCREASE; FATIGUE; HUMAN; INTERVENTION STUDY; LOW DRUG DOSE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; RIGIDITY; SEDATION; SIDE EFFECT; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; FATTY ACIDS, OMEGA-3; HUMANS; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 84856514475     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799316172     Document Type: Article

References (94)

1. Sullivan HS. The onset of schizophrenia. Am J Psychiatry 1927; 84(1): 105-34.
2. Cameron DE. Early schizophrenia. Am J Psychiatry 1938; 95(3): 567-82.
3. Meares A. The diagnosis of prepsychotic schizophrenia. Lancet 1959; 1(7063): 55-8.
4. Falloon IR. Early intervention for first episodes of schizophrenia: a preliminary exploration. Psychiatry 1992; 55(1): 4-15.
5. Birchwood M, Macmillan F. Early intervention in schizophrenia. Aust N Z J Psychiatry 1993; 27(3): 374-8.
6. CDHAC. Promotion, prevention and early intervention for mental health-a monograph. Canberra: Commonwealth Department of Health and Aged Care 2000.
7. EC. Green Paper - Improving mental health of the population: Towards a strategy on mental health for the European Union. Brüssel: European Communities 2005.
8. BMG. Maßnahmen des Bundesministeriums für Gesundheit zur Umsetzung nationaler Gesundheitsziele. Berlin: Bundesministerium für Gesundheit; 2007 [cited 2011 May 10]; Available from: www.gesundheitsziele.de.
9. WHO. Prevention of mental disorders: effective interventions and policy options. Organization WH, editor. Geneva: World Health Organization 2004.
10. Häfner H, Maurer K, Löffler W, et al. Modeling the early course of schizophrenia. Schizophr Bull 2003; 29(2): 325-40.
11. Huber G, Gross G, Schüttler R. Schizophrenie. Verlaufs- und sozialpsychiatrische Langzeituntersuchungen an den 1945-1959 in Bonn hospitalisierten schizophrenen Kranken. Monogr Gesamtgeb Psychiatr Psychiatry Ser 1979; 21: 1-399.
12. Schultze-Lutter F, Ruhrmann S, Berning J, Maier W, Klosterkotter J. Basic symptoms and ultrahigh risk criteria: symptom development in the initial prodromal state. Schizophr Bull 2010; 36(1): 182-91.
13. Ruhrmann S, Schultze-Lutter F, Klosterkotter J. Probably at-risk, but certainly ill - Advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr Res 2010; 120(1-3): 23-37.
14. Huber G. Reine Defektsyndrome und Basisstadien endogener Psychosen. Fortschr Neurol Psychiatr 1966; 34: 409-26.
15. Schultze-Lutter F. Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. Schizophr Bull 2009; 35(1): 5-8.
16. Schultze-Lutter F, Addington J, Ruhrmann S, Klosterkötter J. Schizophrenia Proneness Instrument - Adult version (SPI-A). Rome: Giovanni Fioriti 2007.
17. Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull 2003; 29(4): 703-15.
18. Yung AR, Yuen HP, McGorry PD, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry 2005; 39(11-12): 964-71.
19. Klosterkotter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 2001; 58(2): 158-64.
20. Schultze-Lutter F, Klosterkötter J, Picker H, Steinmeyer E, Ruhrmann S. Predicting first-episode psychosis by basic symptom criteria. Clinical Neuropsychiatry 2007; 4(1): 11-22.
21. Ruhrmann S, Bechdolf A, Kuhn KU, et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry Suppl 2007; 51: s88-95.
22. Häfner H, Maurer K, Ruhrmann S, et al. Early detection and secondary prevention of psychosis: facts and visions. Eur Arch Psychiatry Clin Neurosci 2004; 254(2): 117-28.
23. Bechdolf A, Wagner M, Veith V, et al. Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Intervention in Psychiatry 2007; 1(1): 71-8.
24. Ruhrmann S, Schultze-Lutter F, Salokangas RK, et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry 2010; 67(3): 241-51.
25. McGorry PD, Nelson B, Amminger GP, et al. Intervention in individuals at ultra high risk for psychosis: a review and future directions. J Clin Psychiatry 2009; 70(9): 1206-12.
26. Bechdolf A, Müller H, Stützer H, et al. Rationale and baseline characteristics of PREVENT: A second generation intervention trial in subjects at-risk (prodromal) of developing first episode psychosis evaluating cognitive behaviour therapy, aripiprazole and placebo for the prevention of psychosis. Schizophrenia Bull in press.
27. Schultze-Lutter F, Schimmelmann BG, Ruhrmann S. The Near Babylonian Speech Confusion in Early Detection of Psychosis. Schizophr Bull 2011.
28. McGlashan T, Walsh B, Woods SW. The psychosis-risk syndrome. Handbook for diagnosis and follow-up. New York, N.Y.: Oxford University Press 2010.
29. Maurer K, Hörrmann F, Trendler G, Schmidt M, Häfner H. Identification of psychosis risk by the Early Recognition Inventory (ERIraos) - description of the schedules and preliminary results on reliability and validity of the checklist. Nervenheilkunde 2006; 25(1-2): 11-6.
30. Kendler KS, McGuire M, Gruenberg AM, et al. The Roscommon Family Study. I. Methods, diagnosis of probands, and risk of schizophrenia in relatives. Arch Gen Psychiatry 1993; 50(7): 527-40.
31. Gordon RS, Jr. An operational classification of disease prevention. Public Health Rep 1983; 98(2): 107-9.
32. Mrazek PJ, Haggerty HJ. Reducing risks for mental disorders: frontiers for preventive research. Washington DC: Academy Press 1994.
33. McGorry PD, Yung AR, Phillips LJ. The close-in or ultra highrisk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. Schizophr Bull 2003; 29(4): 771-90.
34. Bell RQ. Multiple-risk cohorts and segmenting risk as solutions to the problem of false positives in risk for the major psychoses. Psychiatry 1992; 55(4): 370-81.
35. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res 2004; 67(2-3): 131-42.
36. Yung AR, Nelson B, Stanford C, et al. Validation of prodromal criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophr Res 2008; 105(1-3): 10-7.
37. Kirkbride JB, Fearon P, Morgan C, et al. Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study. Arch Gen Psychiatry 2006; 63(3): 250-8.
38. Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008; 65(1): 28-37.
39. Riecher-Rossler A, Pflueger MO, Aston J, et al. Efficacy of using cognitive status in predicting psychosis: a 7-year follow-up. Biol Psychiatry 2009; 66(11): 1023-30.
40. Yung AR, Phillips LJ, Nelson B, et al. Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6- month analysis. J Clin Psychiatry 2011; 72(4): 430-40.
41. McGlashan TH, Zipursky RB, Perkins D, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163(5): 790-9.
42. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 2.3.1. [updated 2010 September 192011 May 10]; Available from: www.openepi.com.
43. Koutsouleris N, Meisenzahl EM, Davatzikos C, et al. Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. Arch Gen Psychiatry 2009; 66(7): 700-12.
44. Bodatsch M, Ruhrmann S, Wagner M, et al. Prediction of psychosis by mismatch negativity. Biol Psychiatry 2011; 69(10): 959-66.
45. Addington J, Van Mastrigt S, Hutchinson J, Addington D. Pathways to care: help seeking behaviour in first episode psychosis. Acta Psychiatr Scand 2002; 106(5): 358-64.
46. Köhn D, Pukrop R, Niedersteberg A, et al. [Pathways to care: helpseeking behavior in first-episode psychosis]. Fortschr Neurol Psychiatr 2004; 72(11): 635-42.
47. Singh SP, Grange T. Measuring pathways to care in first-episode psychosis: a systematic review. Schizophr Res 2006; 81(1): 75-82.
48. Haynes RB, Sackett DL, Guyatt GH, Tugwell P. Clinical epidemiology. 3rd ed. Philadelphia: Lippincott Williams & Williams 2006.
49. Hanssen MS, Bijl RV, Vollebergh W, van Os J. Self-reported psychotic experiences in the general population: a valid screening tool for DSM-III-R psychotic disorders? Acta Psychiatr Scand 2003; 107(5): 369-77.
50. Schultze-Lutter F, Ruhrmann S, Klosterkotter J. Early detection of psychosis - establishing a service for persons at risk. Eur Psychiatry 2009; 24(1): 1-10.
51. Simon AE, Dvorsky DN, Boesch J, et al. Defining subjects at risk for psychosis: A comparison of two approaches. Schizophr Res 2006; 81(1): 83-90.
52. Lencz T, Smith CW, Auther A, Correll CU, Cornblatt B. Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr Res 2004; 68(1): 37-48.
53. Velthorst E, Nieman DH, Linszen D, et al. Disability in people clinically at high risk of psychosis. Br J Psychiatry 2010; 197(4): 278-84.
54. Ruhrmann S, Paruch J, Bechdolf A, et al. Reduced subjective quality of life in persons at risk for psychosis. Acta Psychiat Scand 2008; 117(5): 357-68.
55. Cornblatt BA, Auther AM, Niendam T, et al. Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophr Bull 2007; 33(3): 688-702.
56. Addington J, Penn D, Woods SW, Addington D, Perkins DO. Social functioning in individuals at clinical high risk for psychosis. Schizophr Res 2008; 99(1-3): 119-24.
57. Fusar-Poli P, Meneghelli A, Valmaggia L, et al. Duration of untreated prodromal symptoms and 12-month functional outcome of individuals at risk of psychosis. Br J Psychiatry 2009; 194(2): 181-2.
58. Fusar-Poli P, Perez J, Broome M, et al. Neurofunctional correlates of vulnerability to psychosis: a systematic review and metaanalysis. Neurosci Biobehav Rev 2007; 31(4): 465-84.
59. Pantelis C, Velakoulis D, Wood SJ, et al. Neuroimaging and emerging psychotic disorders: the Melbourne ultra-high risk studies. Int Rev Psychiatry 2007; 19(4): 371-81.
60. Smieskova R, Fusar-Poli P, Allen P, et al. Neuroimaging predictors of transition to psychosis--a systematic review and meta-analysis. Neurosci Biobehav Rev 2010; 34(8): 1207-22.
61. Witthaus H, Kaufmann C, Bohner G, et al. Gray matter abnormalities in subjects at ultra-high risk for schizophrenia and first-episode schizophrenic patients compared to healthy controls. Psychiatry Res 2009; 173(3): 163-9.
62. Brockhaus-Dumke A, Tendolkar I, Pukrop R, et al. Impaired mismatch negativity generation in prodromal subjects and patients with schizophrenia. Schizophr Res 2005; 73(2-3): 297-310.
63. van Tricht MJ, Nieman DH, Koelman JH, et al. Auditory ERP components before and after transition to a first psychotic episode. Biol Psychol 2011.
64. Pukrop R, Ruhrmann S, Schultze-Lutter F, et al. Neurocognitive indicators for a conversion to psychosis: comparison of patients in a potentially initial prodromal state who did or did not convert to a psychosis. Schizophr Res 2007; 92(1-3): 116-25.
65. Seidman LJ, Giuliano AJ, Meyer EC, et al. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry 2010; 67(6): 578-88.
66. Miller TJ, Zipursky RB, Perkins D, et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the prodromal sample. Schizophr Res 2003; 61(1): 19-30.
67. McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59(10): 921-8.
68. Phillips LJ, McGorry PD, Yuen HP, et al. Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr Res 2007; 96(1-3): 25-33.
69. McGlashan TH, Zipursky RB, Perkins D, et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr Res 2003; 61(1): 7-18.
70. Ruhrmann S, Schultze-Lutter F, Maier W, Klosterkötter J. Pharmacological intervention in the initial prodromal phase of psychosis. Eur Psychiatry 2005; 20(1): 1-6.
71. Cornblatt BA, Lencz T, Smith CW, et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry 2007; 68(4): 546-57.
72. Amminger GP, Schafer MR, Papageorgiou K, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010; 67(2): 146-54.
73. Nuechterlein KH. Vulnerability models for schizophrenia: State of the art. In: Häfner H, Gattaz WF, Janzarik W, editors. Search for the causes of schizophrenia. Heidelberg: Springer; 1987. p. 297-316.
74. Yung AR, Stanford C, Cosgrave E, et al. Testing the Ultra High Risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophr Res 2006; 84(1): 57-66.
75. Ruhrmann S, Schultze-Lutter F, Klosterkötter J. Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsy chiatry 2003; 36 Suppl 3: S162-7.
76. Woods SW, Breier A, Zipursky RB, et al. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry 2003; 54(4): 453-64.
77. Kostis JB. Treating hypercholesterolemia and hypertension based on lifetime global risk. Am J Cardiol 2007; 100(1): 138-42.
78. Fusar-Poli P, Valmaggia L, McGuire P. Can antidepressants prevent psychosis? Lancet 2007; 370(9601): 1746-8.
79. Amore M, Jori MC. Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol 2001; 16(6): 317-24.
80. Kumra S, Oberstar JV, Sikich L, et al. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 2008; 34(1): 60-71.
81. Moreno C, Arango C, Parellada M, Shaffer D, Bird H. Antidepressants in child and adolescent depression: where are the bugs? Acta Psychiatr Scand 2007; 115(3): 184-95.
82. Papakostas GI. Tolerability of modern antidepressants. J Clin Psychiatry 2008; 69 Suppl E1: 8-13.
83. Schultze-Lutter F, Ruhrmann S, Klosterkötter J. Can schizophrenia be predicted phenomenologically? In: Johannesen JO, Martindale BV, Cullberg J, editors. Evolving psychosis: different stages, different treatments. Hove: Routledge; 2006. p. 104-23.
84. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9.
85. Woods SW, Walsh B, Pearlson GD, McGlashan TH. Glycine treatment of prodromal symptoms. Schizophr Res 2006; 86: S7-S.
86. Berger G, Wood S, Ross M, et al. Neuroprotective effects of low dose lithium in individuals at ultra-high risk for psychosis. Early Intervention in Psychiatry 2008; 2: A28-A.
87. Wood SJ, Berger GE, Dell'Olio M, et al. Effects of low dose lithium on hippocampal neuropathology in people at ultra-high risk for psychosis. Biol Psychiat 2007; 61(8): 259s-60s.
88. Woods SW, Walsh BC, Saksa JR, McGlashan TH. The case for including Attenuated Psychotic Symptoms Syndrome in DSM-5 as a psychosis risk syndrome. Schizophr Res 2010; 123(2-3): 199-207.
89. APA. DSM-V development: Proposed Draft Revisions to DSM Disorders and Criteria 2010 [cited 2011 May 30]; Available from: http://www.dsm5.org/ProposedRevisions/Pages/proposedrevision.a spx?rid=412.
90. Woods SW, Tully EM, Walsh BC, et al. Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Br J Psychiatry Suppl 2007; 51: s96-101.
91. Bechdolf A, Veith V, Vogeley K, et al. PREVENT: background and rational of a clinical study comparing the preventive effects of CBT, aripriprazole and placebo in persons at-risk for psychosis. Nervenarzt 2008; 79(Suppl. 1): S37.
92. Ilyukhina VA, Sychev AG, Shcherbakova NI, Baryshev GI, Denisova VV. The omega-potential: a quantitative parameter of the state of brain structures and of the individual. II. Possibilities and limitations of the use of the omega-potential for rapid assessment of the state of the individual. Hum Physiol 1982; 8(5): 328-39.
93. McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust Nz J Psychiat 2006; 40(8): 616-22.
94. Ruhrmann S, Schultze-Lutter F, Linszen D, et al. Negative Symptoms and Transition to a First Episode of Psychosis-Findings from EPOS. Schizophrenia Bull 2011; 37: 20-1.